SLC5A2 and heart failure: The EMPEROR-reduced trial further exemplified the benefits of SGLT2 inhibitors as there was a 25% lower combined risk of cardiovascular death or heart failure hospitalization in patients receiving empagliflozin vs. placebo [31].